Are statins indicated in the prevention of cerebral infarct?;Estan indicadas las estatinas en la prevencion del infarto cerebral?

Revista de Neurologia

Volumn 30, Issue 7, 2000, Pages 671-693

  Diez Tejedor, Exuperio ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Carotid stenosis; Cerebral infarct; Epidemiology; Ischemic cardiopathy; Lipids; Statins; Stroke

Indexed keywords

PRAVASTATIN; STATIN; HYPOCHOLESTEROLEMIC AGENT;

ARTICLE; ATHEROMA; BRAIN INFARCTION; CAROTID ARTERY OBSTRUCTION; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; PRIMARY PREVENTION; STROKE; RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CAROTID STENOSIS; CEREBRAL INFARCTION; HUMANS; HYPERCHOLESTEROLEMIA; PRAVASTATIN; RISK FACTORS;

EID: 0034174117     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3007.99392     Document Type: Article

References (31)

1. Atkins D, Psaty B, Koepsell T, Longstreth W, Larson E. Cholesterol reduction and the risk for stroke in men: a meta-analysis of randomized controlled trials. Ann Intern Med 1993; 119: 136-45.
2. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995; 92: 2419-25.
3. Crouse J III, Byington R, Bond M, Espeland M, Craven T, Sprinkle J, McGovern M, et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
4. Dayton S, Pearce M, Hashimoto S, Dixon W, Tomiyasu U. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969; 40 (Suppl II): II1-63.
5. Delanty N, Vaughan C. Vascular effects of statins in stroke. Stroke 1997; 28: 2315-20.
6. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273: 1421-8.
7. Furberg CD, Adams H, Applegat W, Byington R, Espeland M, Hartwell T, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90: 1679-87.
8. Gordon T, Kannel W, Castelli W, Dawber T. Lipoproteins, cardiovascular disease, and death: the Framingham Study. Arch Intern Med 1981; 141: 1128-31.
9. Hebert P, Gazino J, Chan K, Hennekens C. Cholesterol lowering with statin drugs: risk of stroke and total mortality. JAMA 1997; 278: 313-21.
10. Iso H, Jacobs D Jr, Wentworth D, Neaton J, Cohen J, for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 1989; 320: 904-10.
11. Kagan A, Popper J, Rhoads G. Factors related to stroke incidence in Hawaiian Japanese men: the Honolulu Heart Study. Stroke 1980; 11: 14-21.
12. Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. Br Med J 1994; 309: 11-5.
13. Lipid Research Clinics Program. The Lipids Research clinics coronary prevention trial results. I: Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
14. Marta-Moreno J, Echeandia C, Oliveros-Cid A, Figuerola A, Mola S. Estatinas (inhibidores de la HMG-CoA reductasa), colesterol e ictus. Rev Neurol 1998; 27: 827-30.
15. Martin R, Bogousslavsky J, for the Lausanne Stroke Registry Group. Mechanisms of late stroke after myocardial infarct: the Lausanne Stroke Registry. J Neurol Neurosurg Psychiatry 1993; 56: 760-4.
16. Mercuri M, Bond M, Sirtori C. Pravastatin reduces carotid intima media trickiness progression in an asymptomatic hypercholesterolemic Mediterranean population: the carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996; 101: 627-34.
17. Pedersen T, Kjekschus J, Pyorala K, Olsson A, Cook T, Musliner T, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998; 81: 333-5
18. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53.
19. Qizilbash N, Duffy S, Warlow C, Mann J. Lipids are risk factors for inchaemic stroke: overview and review. Cerebrovasc Dis 1992; 2: 127-36
20. Sacks F, Pfeffer M, Moyé L, Brown L, Hamm P, Cole T, et al, for the Care investigators. Rationales and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE). Am J Cardiol 1991; 68: 1436-46. [Erratum Am J Cardiol 1992; 69: 574].
21. Sacks F, Pfeffer M, Moyé L, Rouleau J, Rutherford J, Cole T, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
22. Salonen J, Puska P, Tuomilehto J, Homan K. Relation of blood pressure, serum lipids, and smoking to the risk of cerebral stroke. Stroke 1982; 13: 327-33.
23. Salonen R, et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758-64.
24. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
25. Tanaka H, Ueda Y, Hayashi M, Date C, Baba T, Yamashita H, et al. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 1982; 13: 62-73.
26. Tell G, Crouse J, Furberg C. Relation between blood lipids, lipoproteins and cerebrovascular atherosclerosis: a review. Stroke 1988; 19: 423-30.
27. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360-81.
28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
29. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72: 1031-7.
30. Veterans Administration Cooperative Study Group. The treatment of cerebrovascular disease with clofibrate. Stroke 1973; 4: 684-93.
31. Wolf P, Kannel W, Verter J. Current status of risk factor for stroke. Neurol Clin 1983; 1: 317-43.